Lithium toxicity profile: a systematic review and meta-analysis.
BACKGROUND: Lithium is a widely used and effective treatment for mood disorders. There has been concern about its safety but no adequate synthesis of the evidence for adverse effects. We aimed to undertake a clinically informative, systematic toxicity profile of lithium. METHODS: We undertook a sys...
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
2012
|
| _version_ | 1826289574619381760 |
|---|---|
| author | McKnight, R Adida, M Budge, K Stockton, S Goodwin, G Geddes, J |
| author_facet | McKnight, R Adida, M Budge, K Stockton, S Goodwin, G Geddes, J |
| author_sort | McKnight, R |
| collection | OXFORD |
| description | BACKGROUND: Lithium is a widely used and effective treatment for mood disorders. There has been concern about its safety but no adequate synthesis of the evidence for adverse effects. We aimed to undertake a clinically informative, systematic toxicity profile of lithium. METHODS: We undertook a systematic review and meta-analysis of randomised controlled trials and observational studies. We searched electronic databases, specialist journals, reference lists, textbooks, and conference abstracts. We used a hierarchy of evidence which considered randomised controlled trials, cohort studies, case-control studies, and case reports that included patients with mood disorders given lithium. Outcome measures were renal, thyroid, and parathyroid function; weight change; skin disorders; hair disorders; and teratogenicity. FINDINGS: We screened 5988 abstracts for eligibility and included 385 studies in the analysis. On average, glomerular filtration rate was reduced by -6·22 mL/min (95% CI -14·65 to 2·20, p=0·148) and urinary concentrating ability by 15% of normal maximum (weighted mean difference -158·43 mOsm/kg, 95% CI -229·78 to -87·07, p<0·0001). Lithium might increase risk of renal failure, but the absolute risk was small (18 of 3369 [0·5%] patients received renal replacement therapy). The prevalence of clinical hypothyroidism was increased in patients taking lithium compared with those given placebo (odds ratio [OR] 5·78, 95% CI 2·00-16·67; p=0·001), and thyroid stimulating hormone was increased on average by 4·00 iU/mL (95% CI 3·90-4·10, p<0·0001). Lithium treatment was associated with increased blood calcium (+0·09 mmol/L, 95% CI 0·02-0·17, p=0·009), and parathyroid hormone (+7·32 pg/mL, 3·42-11·23, p<0·0001). Patients receiving lithium gained more weight than did those receiving placebo (OR 1·89, 1·27-2·82, p=0·002), but not those receiving olanzapine (0·32, 0·21-0·49, p<0·0001). We recorded no significant increased risk of congenital malformations, alopecia, or skin disorders. INTERPRETATION: Lithium is associated with increased risk of reduced urinary concentrating ability, hypothyroidism, hyperparathyroidism, and weight gain. There is little evidence for a clinically significant reduction in renal function in most patients, and the risk of end-stage renal failure is low. The risk of congenital malformations is uncertain; the balance of risks should be considered before lithium is withdrawn during pregnancy. Because of the consistent finding of a high prevalence of hyperparathyroidism, calcium concentrations should be checked before and during treatment. FUNDING: National Institute for Health Research Programme Grant for Applied Research. |
| first_indexed | 2024-03-07T02:30:57Z |
| format | Journal article |
| id | oxford-uuid:a736fefd-981f-4615-af0d-9ac71c23cd52 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:30:57Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:a736fefd-981f-4615-af0d-9ac71c23cd522022-03-27T02:53:02ZLithium toxicity profile: a systematic review and meta-analysis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a736fefd-981f-4615-af0d-9ac71c23cd52EnglishSymplectic Elements at Oxford2012McKnight, RAdida, MBudge, KStockton, SGoodwin, GGeddes, J BACKGROUND: Lithium is a widely used and effective treatment for mood disorders. There has been concern about its safety but no adequate synthesis of the evidence for adverse effects. We aimed to undertake a clinically informative, systematic toxicity profile of lithium. METHODS: We undertook a systematic review and meta-analysis of randomised controlled trials and observational studies. We searched electronic databases, specialist journals, reference lists, textbooks, and conference abstracts. We used a hierarchy of evidence which considered randomised controlled trials, cohort studies, case-control studies, and case reports that included patients with mood disorders given lithium. Outcome measures were renal, thyroid, and parathyroid function; weight change; skin disorders; hair disorders; and teratogenicity. FINDINGS: We screened 5988 abstracts for eligibility and included 385 studies in the analysis. On average, glomerular filtration rate was reduced by -6·22 mL/min (95% CI -14·65 to 2·20, p=0·148) and urinary concentrating ability by 15% of normal maximum (weighted mean difference -158·43 mOsm/kg, 95% CI -229·78 to -87·07, p<0·0001). Lithium might increase risk of renal failure, but the absolute risk was small (18 of 3369 [0·5%] patients received renal replacement therapy). The prevalence of clinical hypothyroidism was increased in patients taking lithium compared with those given placebo (odds ratio [OR] 5·78, 95% CI 2·00-16·67; p=0·001), and thyroid stimulating hormone was increased on average by 4·00 iU/mL (95% CI 3·90-4·10, p<0·0001). Lithium treatment was associated with increased blood calcium (+0·09 mmol/L, 95% CI 0·02-0·17, p=0·009), and parathyroid hormone (+7·32 pg/mL, 3·42-11·23, p<0·0001). Patients receiving lithium gained more weight than did those receiving placebo (OR 1·89, 1·27-2·82, p=0·002), but not those receiving olanzapine (0·32, 0·21-0·49, p<0·0001). We recorded no significant increased risk of congenital malformations, alopecia, or skin disorders. INTERPRETATION: Lithium is associated with increased risk of reduced urinary concentrating ability, hypothyroidism, hyperparathyroidism, and weight gain. There is little evidence for a clinically significant reduction in renal function in most patients, and the risk of end-stage renal failure is low. The risk of congenital malformations is uncertain; the balance of risks should be considered before lithium is withdrawn during pregnancy. Because of the consistent finding of a high prevalence of hyperparathyroidism, calcium concentrations should be checked before and during treatment. FUNDING: National Institute for Health Research Programme Grant for Applied Research. |
| spellingShingle | McKnight, R Adida, M Budge, K Stockton, S Goodwin, G Geddes, J Lithium toxicity profile: a systematic review and meta-analysis. |
| title | Lithium toxicity profile: a systematic review and meta-analysis. |
| title_full | Lithium toxicity profile: a systematic review and meta-analysis. |
| title_fullStr | Lithium toxicity profile: a systematic review and meta-analysis. |
| title_full_unstemmed | Lithium toxicity profile: a systematic review and meta-analysis. |
| title_short | Lithium toxicity profile: a systematic review and meta-analysis. |
| title_sort | lithium toxicity profile a systematic review and meta analysis |
| work_keys_str_mv | AT mcknightr lithiumtoxicityprofileasystematicreviewandmetaanalysis AT adidam lithiumtoxicityprofileasystematicreviewandmetaanalysis AT budgek lithiumtoxicityprofileasystematicreviewandmetaanalysis AT stocktons lithiumtoxicityprofileasystematicreviewandmetaanalysis AT goodwing lithiumtoxicityprofileasystematicreviewandmetaanalysis AT geddesj lithiumtoxicityprofileasystematicreviewandmetaanalysis |